NEWS

2012-12-10

Syncom collaborates in PET-MRI project for early diagnosis of prostate cancer

Recently a new research project aiming at the early diagnosis of prostate cancer was started. The project is a collaboration of the MIRA institute, the University of Twente, UMC Groningen and Groningen University, UMC St. Radboud and several companies: Siemens, PolyVation, 20Med, FutureChemistry, Micronit, Veenstra and Syncom. This project with an estimated budget of 5.7 million euros is financially supported by the Provinces of Overijssel (1.4m) and Gelderland (0.6m). The recent development of combined PET-MRI systems may significantly improve medical imaging. However, so far, appropriate dual imaging agents are still missing. Syncom will be involved in the research and development of a suitable dual probe for PET-MRI imaging of prostate cancer in order to make diagnosis less invasive and painful and prevent over-diagnosis, unnecessary biopsies and unnecessary treatment.

2012-11-07

Chemicals from biomass: soda bottle from biomass

The Dutch newspaper "DAGBLAD VAN HET NOORDEN" published an article titled "Frisdrankfles uit biomassa" (English "Soda bottle from biomass") on Saturday November 3, 2012. The article gives an update on technology that has been developed by BioBTX in collaboration with the University of Groningen and Syncom. The consortium investigates the optimization of the production of BTX chemicals from biomass. The project is supported by the European Union and the province of Groningen.

Related news-item:Chemicals from biomass: Syncom develops Green Chemistry (2012-03-26)

2012-09-27

FIGON Dutch Medicines Days 2012 in Lunteren

Syncom's senior scientist Jean-Paul Seerden will present the preliminary results of TI Pharma project D5-301 of the consortium partners Syncom, UMCG and Synvolux at the FIGON Dutch Medicines Days 2012 in Lunteren on Tuesday October 2nd, 2012.  

More information about this subject: TI Pharma poster FIGON DMD october 2012.pdf

Abstract:

Development of potent p38 MAPK inhibitors with favourable characteristics for formulation into SAINT-O-Somes
 J.P.G.Seerden¹, T.E. Woudenberg-Vrenken², R.M. Kellogg¹, E.G. Talman³, M.H.J. Ruiters³, G. Molema², J.A.A.M. Kamps²,
¹Syncom B.V.; ² Dept. of Pathology and Medical Biology, Medical Biology Section, University Medical Center Groningen,  ³ Synvolux Therapeutics B.V., Groningen, The Netherlands

Introduction: Many pharmacologically potent kinase inhibitors cause toxicity in humans. Improvement of physicochemical properties for proper formulation into targeted lipid-based carriers can prevent side effects and increase therapeutic efficacy.
Methods: 70 new 4,5-diaryl substituted imidazoles and oxazoles were prepared using structure-based drug design integrated with desired physicochemical properties. p38 MAPK inhibition was determined using radiometric kinase IC₅₀ profiling assays. Encapsulation into SAINT-O-Somes was done by thin film hydration and remote loading methods. Anti E-selectin antibodies were conjugated to SUS-loaded SAINT-O-Somes to specifically target activated endothelial cells. Downstream effects on the p38 MAPK mediated proinflammatory genes (COX-2, IL-6)  in TNF-alpha activated HUVEC were analyzed using qPCR techniques.
Results: p38 MAPK IC₅₀: 8 nM to 56 microM. Downregulation proinflammatory gene expression up to 65%. Encapsulation efficiencies: 1-5%. Formulation stability depends on physicochemical properties of the drug and lipid composition.
Conclusion: a widely applicable synthetic and formulation strategy is in development.

2012-07-03

MEET SYNCOM at ChemOutsourcing 2012

Syncom will be present at the ChemOutsourcing 2012 conference, September 10-13 in New Jersey. ChemOutsourcing is the 5th version of the unique, annual pharmaceutical chemistry show, with over 100 speakers, mostly chemists from pharma and biotech companies, and an exhibition for 100 chemistry service providers. The conference discussions center around Chemistry Sourcing/Outsourcing, Process R&D, Chemical Development, CMC, Procurement, Medicinal Chemistry, Drug Discovery, and New Chemical Technologies.

Meet Syncom at booth # 28 at ChemOutsourcing 2012

2012-07-02

MEET SYNCOM at ISMC 2012

Syncom will be present at the EFMC-ISMC 2012, September 2 - 6, 2012 in Berlin, Germany. The ISMC-2012 is ‘22nd International Symposium on Medicinal Chemistry’ by the European Federation for Medicinal Chemistry (EFMC). This biannual symposium is recognized worldwide as one of the leading Medicinal Chemistry meetings. The ISMC attracts a large international attendance varying between 1200 and 1500 participants from all over the world. Syncom will have a booth together with Integrex Research, a CRO offering Integrated drug discovery services.

Meet Syncom at booth # 25 at the ISMC 2012